Giuseppe Del Giudice

USPTO Granted Patents = 11 (Patent Applications = 9)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

Berkshire, GB (2020 - 2022)
Siena, IT (2004 - 2023)

Company Filing History:

Years Active: 2004-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11707520 - Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture (2023-07-25),

2. 11406701 - Vaccination of immunocompromised subjects (2022-08-09),

3. 10842867 - Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture (2020-11-24),

4. 10716844 - Vaccination of immunocompromised subjects (2020-07-21),

5. 9901630 - Adjuvant-sparing multi-dose influenza vaccination regimen (2018-02-27),

6. 9421251 - Rapid responses to delayed booster immunisations (2016-08-23),

7. 8808686 - Adjuvant-sparing multi-dose influenza vaccination regimen (2014-08-19),

8. 8697087 - Influenza vaccines including combinations of particulate adjuvants and immunopotentiators (2014-04-15),

9. H0002283 - Vaccines for protecting against influenza (2013-09-02),

10. 7056521 - Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants (2006-06-06),

11. 6818222 - Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants (2004-11-16),

Title: The Innovations of Giuseppe Del Giudice: A Pioneer in Vaccine Development

Introduction: Giuseppe Del Giudice, based in Siena, Italy, is an accomplished inventor recognized for his significant contributions to the field of immunology and vaccine development. With a portfolio of 11 patents, Del Giudice has dedicated his career to enhancing vaccine efficacy, particularly for immunocompromised individuals.

Latest Patents: Among his latest innovations are two pivotal patents. The first focuses on adjuvanted vaccines featuring non-virion antigens prepared from influenza viruses grown in cell culture. This immunogenic composition includes a non-virion influenza virus antigen and an adjuvant, with preferred adjuvants comprising oil-in-water emulsions. The second patent outlines methods for improving immune responses to vaccines in immunocompromised individuals, including those undergoing statin therapy. These patents underscore his commitment to advancing healthcare through innovative solutions.

Career Highlights: Del Giudice has made notable impacts in his career, working with esteemed organizations such as Seqirus UK Limited and Novartis AG. His efforts have not only advanced scientific understanding but have also contributed to the public health sector.

Collaborations: Throughout his career, Del Giudice has collaborated with accomplished individuals in the field, including Rino Rappuoli and Derek T O'Hagan. These partnerships have enabled a cross-pollination of ideas and research, further enhancing the quality and impact of his work.

Conclusion: Giuseppe Del Giudice's innovative spirit and dedication to vaccine research exemplify the role of inventors in shaping the future of healthcare. His patents and collaborations have paved the way for significant advancements, ensuring that treatments are more effective, especially for vulnerable populations. As vaccine technology continues to evolve, Del Giudice's contributions will undoubtedly inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.